<p><strong>Patient Selection for Non-Resistant EGFR Mutation-Positive Metastatic NSCLC</strong>: Select patients for first line treatment of metastatic NSCLC with Afatinib based on the presence of non-resistant EGFR mutations in tumor specimens.<br />
<br />
<strong>Recommended Dose</strong>: The recommended dose of Afatinib is 40 mg orally, once daily until disease progression or no longer tolerated by the patient.<br />
<br />
<strong>Renal impairment</strong>: 30 mg orally, once daily in patients with severe renal impairment.<br />
<br />
Instruct patients to take Afatinib at least 1 hour before or 2 hours after a meal.</p>